CCA
IDYA icon

Catalyst Capital Advisors’s IDEAYA Biosciences IDYA Stock Holding History

Catalyst Capital Advisors’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-436
Closed -$4K – 449
2019
Q2 		$4K Buy
+436
New +$4.74K ﹤0.01% 402

Other funds holding IDYA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalyst Capital Advisors's IDYA Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of IDEAYA Biosciences (IDYA) in Q3 2019, closing a stake of 436 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in IDYA in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 24 funds tracked by Wall St. Rank hold IDYA as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining IDEAYA Biosciences position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 436 IDEAYA Biosciences shares in Q3 2019, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in IDEAYA Biosciences in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's IDEAYA Biosciences position peaked at $4K in Q2 2019.
  • 24 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.